Financial Performance - The company's revenue for Q1 2025 was ¥168,896,131.59, a decrease of 31.10% compared to ¥245,116,238.48 in the same period last year[5] - Net profit attributable to shareholders was ¥45,968,405.62, down 34.46% from ¥70,134,618.06 year-on-year[5] - The basic earnings per share decreased by 42.86% to ¥0.04 from ¥0.07 in the same period last year[5] - The company reported a significant decline in net profit excluding non-recurring gains and losses, which was ¥21,141,816.50, down 79.19% from ¥101,583,927.04 in the previous year[5] - The company's net profit for the current period is CNY 45,617,183.33, a decrease of 34.5% compared to CNY 69,675,806.49 in the previous period[20] - Operating profit for the current period is CNY 48,346,156.71, down 32.0% from CNY 71,156,814.33 in the previous period[20] - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥55,992,394.20, a decline of 152.45% compared to ¥106,747,075.24 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -55,992,394.20, compared to a net inflow of CNY 106,747,075.24 in the previous period[23] - Investment activities resulted in a net cash outflow of CNY -131,848,452.89, compared to CNY -24,793,699.08 in the previous period[23] - The company's cash and cash equivalents at the end of the period decreased to CNY 212,037,406.38 from CNY 621,996,815.09 at the end of the previous period[23] - Cash and cash equivalents decreased to ¥328,747,917.07 from ¥411,958,243.66, representing a decline of 20.1%[14] Operating Costs and Expenses - Total operating costs increased to ¥155,955,363.45, up 14.2% from ¥136,620,657.72 in the previous period[18] - The company incurred total sales expenses of CNY 19,904,477.41, an increase of 16.9% from CNY 17,035,038.54 in the previous period[20] - Research and development expenses increased slightly to CNY 28,942,931.49 from CNY 28,053,862.46 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,064,702,839.06, reflecting a 1.43% increase from ¥5,979,019,318.74 at the end of the previous year[5] - Total assets increased to ¥6,064,702,839.06 from ¥5,979,019,318.74, reflecting a growth of 1.4%[16] - Total liabilities rose to ¥438,437,416.35, an increase of 10.1% from ¥398,371,079.36[16] - The equity attributable to shareholders increased by 0.82% to ¥5,618,416,348.02 from ¥5,572,447,942.40 at the end of the previous year[5] - Shareholders' equity increased to ¥5,626,265,422.71 from ¥5,580,648,239.38, a growth of 0.8%[16] Fair Value and Financial Changes - The company's financial expenses increased by 44.14% year-on-year, primarily due to reduced interest income from lower interest rates[9] - The fair value changes in financial assets increased by 157.94%, attributed to the market value fluctuations of holdings in Shouyao Holdings and Xinghao Pharmaceutical[9] - The company reported a significant fair value change gain of CNY 25,524,228.94, compared to a loss of CNY -44,049,648.74 in the previous period[20] Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[18]

双鹭药业（002038）公告，2024年营业收入6.6亿元，同比下降35.15%。归属于上市公司股东的净利 润-7406.57万元，同比下降117.77%。基本每股收益-0.07元/股。公司拟向全体股东每10股派发现金红利 0.2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

双鹭药业（002038）公告，2025年第一季度营业收入为1.69亿元，同比下降31.10%；净利润为4596.84 万元，同比下降34.46%。 ...

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its nitroglycerin spray (brand name: Lishengle), marking a significant milestone as the first domestic approval for this new dosage form [1][2]. Group 1: Drug Information - The nitroglycerin spray is classified as a chemical drug of category 4, with each bottle containing 200 sprays, and each spray delivering 0.4 mg of nitroglycerin [1][2]. - The drug acts quickly, with clinical studies showing that 23.5% of patients experience immediate effects, 62% within one minute, and up to 85.75% within two minutes [2]. - The spray is designed for emergency situations, particularly for acute angina attacks, and is noted for its safety and efficacy compared to aerosol forms, as it does not contain propellants and avoids cooling effects [2][3]. Group 2: Market Context - There are approximately 330 million cardiovascular disease patients in China, with around 11 million suffering from coronary heart disease, indicating a significant market for emergency medications like nitroglycerin [3]. - The overall market size for nitroglycerin formulations (including tablets and aerosols) is estimated to be between 1 billion to 2 billion yuan in 2023, with an expected annual growth rate of 8% to 12% due to the aging population and rising cardiovascular diseases [3]. - The newly approved nitroglycerin spray has been included in the national medical insurance category B, enhancing its market accessibility [3]. Group 3: Company Impact - The approval of the nitroglycerin spray will enrich the company's product portfolio in the cardiovascular medication sector, positioning it as the sole domestic provider of this new dosage form [3].

证券代码：002038 证券简称：双鹭药业 公告编号：2025-005 北京双鹭药业股份有限公司 关于获得硝酸甘油喷雾剂药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的硝酸甘油喷雾剂（商品名：立生乐®）《药品注册 证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：硝酸甘油喷雾剂 剂 型：喷雾剂 规 格：每瓶 200 喷，每喷重量 48mg 含硝酸甘油 0.4mg 注册分类：化学药品 4 类 生产企业：北京双鹭药业股份有限公司 药品批准文号：国药准字 H20253802 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 7 月 20 日向国家药品审评中心递交国内首家上市申请并获得受理。 硝酸甘油喷雾剂为溶液型喷雾剂，通过口腔黏膜直接吸收，无需溶解步骤，通常 30 秒 至 1 分钟即可起效，适合紧急情况（如心 ...

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for Regorafenib tablets, enhancing its portfolio in the oncology sector [1][2]. Group 1: Drug Information - Drug Name: Regorafenib Tablets - Dosage Form: Tablets - Specification: 40mg - Registration Category: Class 4 Chemical Drug - Approval Number: National Drug Approval No. H20253676 - Approval Conclusion: The drug meets the registration requirements as per the relevant laws and regulations [1][2]. Group 2: Market and Application - Regorafenib is a multi-targeted tyrosine kinase inhibitor used for treating various advanced cancers, including: - Metastatic colorectal cancer (mCRC) in patients previously treated with fluorouracil, oxaliplatin, and irinotecan-based chemotherapy [2]. - Gastrointestinal stromal tumors (GIST) in patients previously treated with imatinib and sunitinib [2]. - Hepatocellular carcinoma (HCC) in patients previously treated with sorafenib [2]. - The original Regorafenib was developed by Bayer and Onyx, approved by the FDA in September 2012, and entered the Chinese market in March 2017 [2]. Group 3: Impact on the Company - The approval of Regorafenib will enrich the company's oncology product offerings, potentially increasing its market competitiveness [3].

证券代码：002038 证券简称：双鹭药业 公告编号：2025-004 规 格：40mg 注册分类：化学药品 4 类 生产企业：北京双鹭药业股份有限公司 药品批准文号：国药准字 H20253676 北京双鹭药业股份有限公司 关于获得瑞戈非尼片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的瑞戈非尼片（商品名：欣立尔®）《药品注册证 书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：瑞戈非尼片 剂 型：片剂 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 5 月 22 日向国家药品审评中心递交上市申请并获得受理。 瑞戈非尼（Regorafenib）是一种多靶点酪氨酸激酶抑制剂，广泛应用于多种晚期癌症 的治疗。主要适用于治疗既往接受过以氟尿嘧啶、奥沙利铂和伊立替康为基础的化疗，以 及既往接受过或不适合接受抗 ...

北京双鹭药业股份有限公司 关于获得替米沙坦氨氯地平片（Ⅱ）药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的替米沙坦氨氯地平片（Ⅱ）（商品名：立生源®） 《药品注册证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：替米沙坦氨氯地平片（Ⅱ） 剂 型：片剂 规 格：每片含替米沙坦 40mg 与苯磺酸氨氯地平 5mg（按氨氯地平计） 注册分类：化学药品 4 类 证券代码：002038 证券简称：双鹭药业 公告编号：2025-002 药品批准文号：国药准字 H20253588 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 6 月 25 日向国家药品审评中心递交上市申请并获得受理。 替米沙坦氨氯地平片（Ⅱ）为替米沙坦和氨氯地平组成的复方制剂。替米沙坦属于血 管紧张素 II 受体拮抗剂，通过阻断血管紧张素 II 的 ...

Financial Performance Expectations - The company expects a net profit loss of 32 million yuan for 2024, a decrease of 107.68% compared to the previous year's profit of 52 million yuan[3]. - Total profit is projected to be a loss of 62 million yuan, down 113.34% from a profit of 82 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be 120 million yuan, a decrease of 48.63% from 100 million yuan in the previous year[3]. - The basic earnings per share is projected to be a loss of 0.03 yuan per share, compared to a profit of 0.05 yuan per share last year[3]. Reasons for Profit Decline - The significant decline in net profit is primarily due to a decrease in product prices leading to reduced operating income[5]. - Fluctuations in the stock prices of held trading financial assets resulted in a net profit decrease of 178 million yuan, contrasting with a profit increase of 197 million yuan from stock price fluctuations in 2023[5]. Communication and Reporting - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant discrepancies[4]. - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[6].

北京市君泽君律师事务所 aw Offices 北京市东城区余宝街 89 号余宝大厦 1 层 11F Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing, 电话(Tel):(86 10)6652 3388 传真(Fax):(86 10)6652 3399 网址(Website): www.junzejun.com 关于北京双鹭药业股份有限公司 2024 年第一次临时股东大会的法律意见 致:北京双鹭药业股份有限公司 本所及经办律师依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则(试行)》等规定及本法律意见出具目以前已经发 生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进 行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发表 的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重大遗漏,并承担 相应法律责任。 为出具本法律意见,本所律师出席本次股东大会,审查关于本次股东大会的 公告、出席股东大会的股东资格 ...